Integragen

Integragen Liabilities

The The Liabilities of Integragen (ALINT.PA) as of Nov 8, 2026 is 2.71 M EUR. In the previous year, The Liabilities was 3.76 M EUR — a change of -27.80% (lower).

Liabilities

2.71 MEUR

YoY

-27.80%

Last updated:

In 2025, Integragen's total liabilities amounted to 2.71 M EUR, a -27.80% difference from the 3.76 M EUR total liabilities in the previous year.

The Integragen Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
5.79 M EUR
Jan 1, 2019
4.24 M EUR
Jan 1, 2020
6.65 M EUR
Jan 1, 2021
7.42 M EUR
Jan 1, 2022
6.82 M EUR
Jan 1, 2023
5.99 M EUR
Jan 1, 2024
3.76 M EUR
Jan 1, 2025
2.71 M EUR
The Integragen Liabilities history
YEARLiabilitiesYoY
2.71 MEUR-27.80%
3.76 MEUR-37.24%
5.99 MEUR-12.21%
6.82 MEUR-8.03%
7.42 MEUR+11.55%
6.65 MEUR+56.88%
4.24 MEUR-26.77%
5.79 MEUR+22.68%
4.72 MEUR-25.18%
6.31 MEUR+10.91%
5.69 MEUR+5.16%
5.41 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Integragen Stock analysis

What does Integragen do? IntegraGen SA is a French biotechnology company based in Evry. It was founded in 2000 and is one of the leading companies in developing commercial applications in genomics and biology. The business model of IntegraGen SA consists of providing solutions and services for the diagnosis and treatment of various diseases, such as cancer, neurodegenerative diseases, and other genetically related diseases. The company is divided into two main areas: Diagnostics and Genomics. The Diagnostics area offers a wide range of services to its customers, including an oncology platform for the diagnosis and prediction of cancer using exclusive biomarker sets. Other diagnostic tests are used for the identification of microorganisms in clinical samples and the detection of autoimmune diseases. In the Genomics area, the focus is on the development and sale of PCR kits for genotyping single nucleotide polymorphisms (SNPs) and analysis kits for RNA expression. These solutions allow for the identification and validation of genes in specific biological samples in a way that improves customers' understanding and enables accurate findings. IntegraGen SA is committed to continuously developing new tests and platforms to help its customers achieve more precise diagnoses and better therapies. One notable development of the company is the screening kit "Arisk," which is specifically designed for identifying genotypes that have an increased risk of colorectal cancer. The screening kit uses specific SNPs to ensure that doctors can identify patients who require increased monitoring or even prophylactic surgery. The use of genomics technology and biomarker-based diagnostics is a growing trend in medicine. IntegraGen SA plays a significant role in enabling the integration of genomics into clinical practice, ensuring the best possible diagnosis and treatment for patients. In summary, IntegraGen SA is an innovative biotechnology company dedicated to providing solutions for the diagnosis and prevention of diseases using various technologies. The company is constantly striving to develop new products and services to provide customers and partners with the best possible diagnostic and therapeutic support. Integragen is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Integragen's Liabilities

Integragen's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Integragen's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Integragen's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Integragen's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Integragen’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Integragen stock

The Liabilities of Integragen is 2.71 M EUR in 2025.

The Liabilities of Integragen changed from 3.76 M EUR to 2.71 M EUR, representing a -27.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Integragen since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Integragen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Integragen

All Key Metrics — Integragen